$CLDX: Celldex Presents Emerging MerTK Antibody Program at the Society …

Date: Saturday, November 10th, 2018

Stock(s) mentioned:

Source: Benzinga (https://www.benzinga.com)

Summary: 10, 2018 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data from the Company’s MerTK antibody program in a poster session …

Full article address: https://www.benzinga.com/pressreleases/18/11/g12675543/celldex-presents-emerging-mertk-antibody-program-at-the-society-for-im

Related News:

$LLY $BMY $CELG $CLDX: Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat

$CLDX: Celldex Therapeutics’ Cost-Cutting and Reverse Stock Split Help …

$CLDX: Celldex Therapeutics, Inc. (CLDX) CEO Anthony Marucci on Q4 …

$CLDX: Celldex Therapeutics, Inc (CLDX) Q4 2018 Earnings Conference …

$CLDX: Celldex to Report Full Year 2018 Business/Financial Results and …

$CLDX: The Celldex Reverse Stock Split: What Investors Need To Know

$NMRD $NUVA $CLDX: NuVasive and OHR Pharmaceutical among healthcare gainers …

$CLDX: Post-reverse split trading in Celldex commences today

$CLDX: Post-reverse split trading in Celldex commences today; shares down …

$CLDX $CPHI: Fight Against Cancer Rages on as New Therapy Methods Arise

$CLDX: Here’s Why Celldex Therapeutics Sank on Friday

Latest News:

$BAC: Bank of America’s tech chief is skeptical on blockchain despite having the most patents for it

$YMM9 $ESM9 $NQM9 $SPX $COMP $DJIA: Market Snapshot: Dow futures climb as China trade talks set to resume

$MCD $NKE $RHT: Stocks to Watch: McDonald’s, Canopy Growth, Nike

$C: Citigroup Enters Banking’s Hottest Business With New Payments Unit

$DKS $GOOGL $HD $WMT: Dick’s Tech Chief Goes All Out on In-House Software

$SFTBY $MER-K $BCS $C $DB $MS: Uber Steers $3.1 Billion Careem Deal as Implied Value Gains Ahead of Planned IPO

$TTWO $NTDOY $ATVI $SNE $UBSFY $CCOEY: The Most Popular Video Games in the U.S.

$MKC: McCormick Beats Profit Estimates but Misses Slightly on Sales

$GES: Bear of the Day: Guess (GES)

$MCD $DPZ $CMG $YUM: McDonald’s Buys Dynamic Yield, Boosts Technology Offerings

$ASRT: Will Assertio Therapeutics Continue to Surge Higher?